恶性肿瘤脑转移暨乳腺癌脑转移化疗进展和分子靶向治疗CSCO年会.ppt

* * * * * - This phase ll study evaluated the safety and efficacy of the combination of ERBITUX and FOLFOX-4 as first-line treatment for patients with mCRC. 1. Cervantes A, Casado E, Van Cutsem E et al. Eur J Cancer 2005;Supplement 3:Abstract 642. Updated information presented at ECCO 2005 * * - In this multicenter, open-label, phase II study, patients with metastatic or recurrent CRC received first-line treatment with ERBITUX (400 mg/m2 week 1 and 250 mg/m2 weekly thereafter) plus FOLFOX-4 (every 2 weeks: oxaliplatin 85 mg/m2, day 1; FA 200 mg/m2 2-h infusion and 5-FU 400 mg/m2 i.v. bolus followed by 600 mg/m2 continuous infusion for 22-h, days 1 and 2). - Treatment was continued until disease progression or unacceptable toxicity. 1. Cervantes A, Casado E, Van Cutsem E et al. Eur J Cancer 2005;Supplement 3:Abstract 642. Updated information presented at ECCO 2005 * * - Of the 60 enrolled patients, 46 (77%) were male and the median age was 44.5 years. - The majority of patients were Chinese. - The median Karnofsky performance status was 90%. - The majority of patients (93%) had stage IV disease. Among these patients, 85% had distant metastasis. - The median duration of disease at time of enrolment on the study was 24.2 months. 1. Chan AT, Hsu MM, Goh BC, et al. J Clin Oncol 2005;23:3568-3576 * * - The primary endpoint for the study was the best confirmed overall response. - The secondary endpoints were: -- progression-free survival -- duration of response -- survival time -- safety. 1. Cervantes A, Casado E, Van Cutsem E et al. Eur J Cancer 2005;Supplement 3:Abstract 642. Updated information presented at ECCO 2005 * * * * - Seven patients (12%) had a partial response and a further 29 patients (48%) had stable disease. - Thus, the overall response rate was 12% and the disease control rate was 60%. - The median overall survival was 7.7 months. 1. Chan AT, Hsu MM, Goh BC, et al. J Clin Oncol 2005;23:3568-3576 * * - In addition to the high response rate achieved, ERBITUX